Current management of refractory overactive bladder

Chen, Li‐Chen; Kuo, Hann‐Chorng

doi:10.1111/luts.12304

Cited by 13 publications

(10 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the change in the number of micturitions per day at week 12 in this study was similar to that in studies in Japan 19,20,23 . The change of UUI per day in this study (−75%) was also similar to that in previous studies in Japan and Korea 19,20,23 . The change in volume voided in this study was similar to that reported in the pivotal phase 2 trial by Homma et al 19 …”

Section: Discussionsupporting

confidence: 90%

“…The most frequently observed AEs were dry mouth, and the incidence of AEs was dose dependent. An evaluation of long‐term safety, tolerability, and efficacy of imidafenacin, at a dose of 0.1 mg twice daily for 52 weeks, showed sustained safety and efficacy profiles as those in previous short‐term studies 23 . Similar to previous studies, dry mouth was the most frequent AE in this study, with an incidence of 14.1% in the imidafenacin group.…”

Section: Discussionsupporting

confidence: 84%

“…Comparing the treatment outcomes of this study and other clinical trials 19,20,23 revealed that the changes of variables from baseline to the endpoint were smaller than previous studies. However, the change in the number of micturitions per day at week 12 in this study was similar to that in studies in Japan 19,20,23 . The change of UUI per day in this study (−75%) was also similar to that in previous studies in Japan and Korea 19,20,23 .…”

Section: Discussioncontrasting

confidence: 67%

“…However, it had not been approved in Taiwan. Several drugs for OAB treatment are available, including antimuscarinics, mirabegron, and botulinum toxin A 23 . Approximately 70% of OAB patients are effectively treated with either one or a combination of these drugs.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A double‐blind, randomized, placebo‐controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan

Chuang

Lin

Chow

et al. 2020

LUTS

Self Cite

View full text Add to dashboard Cite

Objective: This study evaluated the efficacy and safety of imidafenacin 0.1 mg twice daily vs placebo for Taiwanese patients with overactive bladder (OAB) after a 12-week oral administration. Methods: This randomized, double-blind, placebo-controlled, two-arm, parallelgroup, prospective study enrolled 118 patients across 11 study sites in Taiwan. Subjects were randomized to imidafenacin or placebo in a 2:1 ratio and entered the 12-week treatment period. At the subsequent visits, efficacy outcome measures and safety assessments were collected for analysis. The primary efficacy outcome was the change in the mean number of micturitions per day. Secondary endpoints included mean changes from baseline in urgency episodes and urge incontinence episodes per day and mean volume voided per micturition. Safety outcomes were also collected and compared between groups. Results: A total of 78 and 40 patients were allocated to the imidafenacin and placebo groups, respectively. Among them, 100 patients (imidafenacin, 65 and placebo, 35) completed the trial. Compared with placebo, imidafenacin was significantly better at reducing the number of micturitions per day (−1.29 ± 2.23 vs-0.46 ± 3.49, P = .0171) and reducing the mean number of urge incontinence episodes (−0.15 ± 0.52 vs 0.04 ± 0.50, P = .0386) at week 12. Adverse events were reported in 35 subjects (44.9%) and 16 (40%) in the imidafenacin and placebo groups, including constipation (n = 3, 4), dry mouth (n = 11, 2), and urinary tract infection (n = 7, 4), respectively. One patient in the imidafenacin group had mild dysuria. Conclusion: Imidafenacin demonstrated efficacy and safety in the treatment of OAB in Taiwanese patients.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 84%

Section: Discussioncontrasting

confidence: 67%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A double‐blind, randomized, placebo‐controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan

Chuang

Lin

Chow

et al. 2020

LUTS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Surgical reconstruction is challenging, and it often requires the use of autografts obtained from the skin, intestine, and other nonurological organs [ 2 ]. Although these techniques can improve the quality of life of the patients [ 3 ], the different anatomy, histological structure, and function of these organs as compared to the urinary system are often associated with important complications and drawbacks for the patient [ 2 ]. Therefore, the development of novel more effective therapeutic alternatives is needed.…”

Section: Introductionmentioning

confidence: 99%

Biofabrication of a Tubular Model of Human Urothelial Mucosa Using Human Wharton Jelly Mesenchymal Stromal Cells

et al. 2021

View full text Add to dashboard Cite

Several models of bioartificial human urothelial mucosa (UM) have been described recently. In this study, we generated novel tubularized UM substitutes using alternative sources of cells. Nanostructured fibrin–agarose biomaterials containing fibroblasts isolated from the human ureter were used as stroma substitutes. Then, human Wharton jelly mesenchymal stromal cells (HWJSC) were used to generate an epithelial-like layer on top. Three differentiation media were used for 7 and 14 days. Results showed that the biofabrication methods used here succeeded in generating a tubular structure consisting of a stromal substitute with a stratified epithelial-like layer on top, especially using a medium containing epithelial growth and differentiation factors (EM), although differentiation was not complete. At the functional level, UM substitutes were able to synthesize collagen fibers, proteoglycans and glycosaminoglycans, although the levels of control UM were not reached ex vivo. Epithelial differentiation was partially achieved, especially with EM after 14 days of development, with expression of keratins 7, 8, and 13 and pancytokeratin, desmoplakin, tight-junction protein-1, and uroplakin 2, although at lower levels than controls. These results confirm the partial urothelial differentiative potential of HWJSC and suggest that the biofabrication methods explored here were able to generate a potential substitute of the human UM for future clinical use.

show abstract

Historical Treatment of SUI and UUI in Women

Tam

Lee

2022

Female Urinary Incontinence

View full text Add to dashboard Cite

Current management of refractory overactive bladder

Cited by 13 publications

References 78 publications

A double‐blind, randomized, placebo‐controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan

A double‐blind, randomized, placebo‐controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan

Biofabrication of a Tubular Model of Human Urothelial Mucosa Using Human Wharton Jelly Mesenchymal Stromal Cells

Historical Treatment of SUI and UUI in Women

Contact Info

Product

Resources

About